bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davidson, R; Feig, B; Hu, W; Khokhar, AR; Kumagai, S; Lee, SJ; Maclean, DS; Mansfield, P; Siddik, ZH; Verschraegen, CF | 1 |
| Hong, WK; Huber, M; Khokhar, AR; Lee, SJ; Murphy, WK; Perez-Soler, R; Shin, DM; Siddik, ZH | 1 |
2 trial(s) available for bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) and Adenocarcinoma
| Article | Year |
|---|---|
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Area Under Curve; Ascites; Carcinoma, Signet Ring Cell; Colorectal Neoplasms; Endometrial Stromal Tumors; Female; Humans; Injections, Intraperitoneal; Liposomes; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Peritoneum; Radionuclide Imaging; Technetium; Tissue Distribution | 2003 |
Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Drug Carriers; Female; Humans; Liposomes; Lung Neoplasms; Male; Mesothelioma; Metabolic Clearance Rate; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Pleura; Pleural Effusion, Malignant; Pleural Neoplasms; Rats | 1997 |